Although several clinical studies have indicated that low apoA-I levels are an independent risk factor for ASCVD [24–26], the underlying mechanism linking apoA-I with the delay of atherosclerotic plaque progression remains unknown. This evidence concerns the gene APOA1 and atherosclerosis.